lung cancer

[SOTIO Biotech] SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.

[Translational Oncology] The authors review previous research on the correlation between chronic stress and the occurrence and development of breast cancer, particularly the molecular mechanism through which chronic stress promotes breast cancer via neurotransmitters secreted by the nervous system.

[JCI Insight] Scientists identified the senescence-like characteristics of cancer-associated fibroblasts (CAFs) after RT and clarify the formidable ability of senescence-like CAFs in promoting NSCLC cell proliferation and radioresistance through the JAK/STAT pathway.

[Checkpoint Therapeutics. Inc. (GlobenewsWire, Inc.)] Checkpoint Therapeutics, Inc. announced the initiation of the CONTERNO study, a global, randomized Phase III trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer.

[Environmental Toxicology] Researchers found that RNF168 expression was positively correlated with the overall survival, first-progression survival, and postprogression survival of lung adenocarcinoma, but not correlated with these survivals of squamous cell carcinoma of lung.

[Scientific Reports] In vitro experimentas focused on the anti-lung adenocarcinoma (LUAD) effects and mechanisms of Tanshinone IIA on LUAD cells via MTT, plate cloning, Annexin V-FITC and PI dual staining, flow cytometry, and western blot assays.